Social determinants of sexual satisfaction in Spain considered from the gender perspective

Aims: To describe gender- and social class-related inequalities in sexual satisfaction and analyze their relationship with self-perceived health status. Methods: This population-based, cross-sectional study included 7384 sexually active people aged 16 years and over residing in Spain in 2009 (3951 men and 3433 women). The explanatory variables were gender, age, social class, share in performing domestic tasks, spend time looking after oneself, collaborate economically in supporting the family, caring for children, self-perceived health status, and the desire to increase or decrease frequency of having sexual relations. Bivariate and multivariate logistic regression models were fitted. Results: Among women, sexual satisfaction declines progressively after age 45. Sexual satisfaction is 1.7 times higher among women who look after themselves and who feel good compared with those who do not. The odds of wanting to increase sex is 3.3 times higher for women who are satisfied compared with women who desire a lower frequency of sexual intercourses; and good perceived health was associated with sexual satisfaction. In satisfied men, the corresponding odds is 1.9 times that of men desiring to reduce their frequency of sex. Conclusions: Gender and social class inequalities are found in sexual satisfaction. This is associated with perceived health status, adding evidence in support of the World Health Organization definition of sexual health.

Metodología para el estudio del brand-placement con enfoque de género: más allá del análisis de contenido

La mayoría de los estudios realizados sobre el tratamiento de género en la publicidad audiovisual se ciñen al formato convencional. Los nuevos formatos no se adecuan siempre a estos patrones. Con este fin, se ha elaborado un protocolo de análisis para estudiar la estructura del brand-placement, como forma no convencional de publicidad, en temas de género en la ficción española. Esta herramienta ha sido sometida a rigurosos controles de fiabilidad y validez con el ánimo de garantizar la confiabilidad y rigurosidad científica de las mismas, tanto en su composición como en su aplicación.

Reflexions al voltant del fòrum de debat «Literatura i identitats: personals i col·lectives»

Aquest article recull les aportacions abocades al voltant de la literatura com a eina per construir les identitats, personals (de gènere i/o sexual) i col·lectives (i/o nacionals) en el fòrum de debat del II Simposi d’Ensenyament de la Literatura i la Llengua. A partir de la proposta de diverses preguntes bastírem ponts de conversa referents a qüestions com ara la formació del professorat en qüestions de gènere, l'explicitació o no a l'aula les diverses formes de desig sexual, el trencament dels tòpics masculí/femení, el paper cabdal de l'etnopoètica com a eina per construir la identitat nacional o la delimitació i popularització dels símbols i mites col·lectius. El text inclou també propostes de textos per a treballar a l'aula els aspectes sobre els quals reflexionem.

Gender analysis of moxifloxacin clinical trials

Purpose: To determine the inclusion of women and the sex-stratification of results in moxifloxacin Clinical Trials (CTs), and to establish whether these CTs considered issues that specifically affect women, such as pregnancy and use of hormonal therapies. Previous publications about women’s inclusion in CTs have not specifically studied therapeutic drugs. Although this type of drug is taken by men and women at a similar rate, adverse effects occur more frequently in the latter. Methods: We reviewed 158 published moxifloxacin trials on humans, retrieved from MedLine and the Cochrane Library (1998–2010), to determine whether they complied with the gender recommendations published by U.S. Food and Drug Administration Guideline. Results: Of a total of 80,417 subjects included in the moxifloxacin CTs, only 33.7% were women in phase I, in contrast to phase II, where women accounted for 45%, phase III, where they represented 38.3% and phase IV, where 51.3% were women. About 40.9% (n = 52) of trials were stratified by sex and 15.3% (n = 13) and 9% (n = 7) provided data by sex on efficacy and adverse effects, respectively. We found little information about the influence of issues that specifically affect women. Only 3 of the 59 journals that published the moxifloxacin CTs stated that authors should stratify their results by sex. Conclusions: Women are under-represented in the published moxifloxacin trials, and this trend is more marked in phase I, as they comprise a higher proportion in the other phases. Data by sex on efficacy and adverse effects are scarce in moxifloxacin trials. These facts, together with the lack of data on women-specific issues, suggest that the therapeutic drug moxifloxacin is only a partially evidence-based medicine.